Molecular Cancer

Scope & Guideline

Unlocking the secrets of cancer biology and treatment.

Introduction

Delve into the academic richness of Molecular Cancer with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationMOL CANCER / Mol. Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'Molecular Cancer' focuses on advancing the understanding of cancer biology, with a particular emphasis on molecular mechanisms, therapeutic applications, and translational research. It covers a wide array of topics related to cancer, integrating insights from molecular biology, genetics, immunology, and clinical applications.
  1. Molecular Mechanisms of Cancer:
    The journal explores the intricate molecular pathways that contribute to cancer development, progression, and metastasis, including genetic mutations, epigenetic modifications, and signaling pathways.
  2. Cancer Immunology and Immunotherapy:
    A significant focus is on the immune system's role in cancer, including the mechanisms of immune evasion by tumors and the development of innovative immunotherapeutic strategies.
  3. Non-coding RNAs and Circular RNAs:
    Research on non-coding RNAs, particularly circular RNAs, is a core area, examining their roles in gene regulation, tumor progression, and potential as therapeutic targets.
  4. Tumor Microenvironment and Metabolism:
    The journal investigates the relationship between tumor cells and their microenvironment, including the metabolic reprogramming of cancer cells and the influence of stromal components on tumor behavior.
  5. Liquid Biopsy and Biomarkers:
    There is a strong emphasis on the development and validation of biomarkers for cancer diagnosis, prognosis, and treatment response, particularly through liquid biopsy technologies.
  6. Targeted and Personalized Therapies:
    Research on targeted therapies, including small molecules and biologics, is prevalent, focusing on identifying actionable mutations and developing personalized treatment approaches.
  7. Translational and Clinical Research:
    The journal aims to bridge basic research with clinical applications, promoting studies that translate laboratory findings into therapeutic strategies for cancer patients.
The landscape of cancer research is continuously evolving, and 'Molecular Cancer' reflects these changes through its published articles. Recent trends indicate a strong focus on cutting-edge research themes that integrate novel technologies and concepts.
  1. Circular RNAs and Their Therapeutic Potential:
    Research on circular RNAs has surged, exploring their mechanisms in cancer biology and their potential as therapeutic targets and biomarkers.
  2. Multi-Omics Approaches:
    There is a growing trend towards integrating multi-omics analyses (genomics, transcriptomics, proteomics) to better understand cancer heterogeneity and inform personalized therapies.
  3. Cancer Immunometabolism:
    The intersection of cancer metabolism and immunology is gaining traction, with studies focusing on how metabolic pathways influence immune responses in the tumor microenvironment.
  4. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene editing technologies in cancer research is rapidly expanding, focusing on their potential to create novel therapies and understand gene function in cancer.
  5. Liquid Biopsy Innovations:
    Innovative approaches to liquid biopsy are emerging, with research targeting circulating tumor DNA and exosomal RNA as non-invasive methods for cancer detection and monitoring.
  6. Targeting the Tumor Microenvironment:
    There is an increasing emphasis on understanding and targeting the tumor microenvironment, particularly the roles of cancer-associated fibroblasts and immune cells in tumor progression and therapy resistance.
  7. Combination Therapies and Personalized Medicine:
    Research is increasingly focused on combination therapies that leverage advances in genomics and immunotherapy, aiming for personalized treatment strategies that improve patient outcomes.

Declining or Waning

While 'Molecular Cancer' maintains a strong focus on emerging themes in cancer research, certain areas have seen a decline in prominence over recent years. These waning themes reflect shifts in research priorities and technological advancements.
  1. Traditional Chemotherapy Mechanisms:
    There has been a noticeable decrease in publications focusing solely on traditional chemotherapy mechanisms, as the field shifts towards exploring combination therapies and personalized approaches.
  2. Basic Cancer Genetics without Functional Insights:
    Research that merely catalogs genetic mutations in cancers without functional validation or therapeutic implications is less frequently seen, as the emphasis has shifted to understanding the functional consequences of these mutations.
  3. In vitro Studies with Limited Clinical Relevance:
    Studies that focus solely on in vitro models without robust links to clinical outcomes or translational potential are becoming less prevalent, as researchers prioritize more clinically relevant models.
  4. Single-Target Therapies:
    Interest in single-target therapies has waned, with a growing focus on combination therapies and multi-target strategies that address the complexity of cancer biology.
  5. Historical Cancer Treatments:
    Research centered on older treatment modalities without novel insights or improvements has decreased, as the field moves towards innovative therapies and precision medicine.

Similar Journals

Cancer Research Communications

Elevating cancer research to new heights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

INTERNATIONAL JOURNAL OF CANCER

Empowering discoveries in oncology and cancer biology.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Cancer Immunology Research

Unraveling the Immune Response in Cancer
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Advancing cancer research through innovation and collaboration.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

GENES CHROMOSOMES & CANCER

Pioneering Research at the Crossroads of Genetics and Cancer.
Publisher: WILEYISSN: 1045-2257Frequency: 12 issues/year

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

ANTICANCER RESEARCH

Exploring Breakthroughs in Oncology and Medicine
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

ONCOLOGY RESEARCH

Exploring Innovative Strategies for Cancer Treatment
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

JOURNAL OF MOLECULAR MEDICINE-JMM

Championing High-Quality Research in Biomedical Science.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

CANCER SCIENCE

Connecting researchers and clinicians to transform cancer care.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Cancer Cell International

Unveiling Innovations in Cancer Biology
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.